
A
PT: 3·10^5 4T1mCherry cells
D0
D7
D8
D11
Blood extraction
D15
D22
D29
D34
Lung metastasis
RT (6Gy/2fx)
muFAP-4-1BBL
muDP47-4-1BBL
B
Primary tumor
4T1-derived tumor
Vehicle
RT
muFAP-4-1BBL
RT+muFAP-4-1BBL
muDP47-4-1BBL
RT+muDP47-4-1BBL
Tumor Volume (mm3)
Days
**
C
Metastasis at day 34
p=0.07
(murine gp70 expression relative to H3)*100
D
Vehicle
RT
muFAP-4-1BBL
muDP47-4-1BBL
RT+muFAP-4-1BBL
RT+muDP47-4-1BBL
Tumor Volume (mm3)
Days

Supplemental Figure 4. muFAP-4-1BBL synergizes with local radiotherapy and reduces metastasis of 4T1-mCherry-derived tumors. (A) Scheme of 7-day 4T1-mCherry tumor engraftment and subsequent treatments with hypofractionated radiotherapy (RT, blue arrows) followed by a treatment with intraperitoneal administration of muFAP-4-1BBL (green arrows) or DP47-4-1BBL (brown arrows). Tumor size of the subcutaneous primary tumor was monitored by caliper measurements and at day 34 lungs were excised for gp70 RT-PCR to monitor lung metastasis burden. (B) Tumor growth of the subcutaneous growing primary tumor over time shown as means ± SEM for each group (Two-way ANOVA); $^{**}p < .01$. (C) Relative gp70 mRNA expression to housekeeping Histone H3 mRNA expression measured by RT-PCR at day 34 as an indicator of lung metastasis burden. Each symbol represents one mouse and means ± SEM are indicated (One-way ANOVA). (D) Individual tumor size growth over time. Each blot is one treatment group as indicate (n=7-12 mice/group). Pooled data from two independent experiments.